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1. Introduction 
1.1. Sepsis 
1.1.1. Historical background 
Sepsis and sepsis-associated conditions have long been discussed during the course of history. It was in 
100 before Christ when Roman scholar and writer Marcus Terentius Varro first noted that “small creatures, 
invisible to the eye, fill the atmosphere, and breathed through the nose cause dangerous diseases” [1]. 
Even though technical possibilities at that time did not allow for specifying these observations any further, 
it was as far back as over 2000 years that people assumed a microbial, infectious genesis of the disease 
that we can only hypothesize might have been most probably sepsis. It was Sir William Osler (1849-1919) 
who observed that the patient appeared to die from the body’s response to the infection rather than from 
the pathogen itself [1]. With this finding, he identified the crux of sepsis over 100 years ago, which makes 
it the dangerous and difficult-to-treat disease it is up to the present day. 
 
1.1.2. Definitions 
The American College of Chest Physicians (ACCP) and the Society of Critical Care Medicine (SCCM) 
held a Consensus Conference in August 1991, which came up with precise, universal definitions for the 
terms systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock and multiple 
organ dysfunction syndrome (MODS), which had been non-existent until then [1, 2] (Table 1). 
Ten years later, several North American and European intensive care societies determined to amend 
these definitions to facilitate their clinical use. But even though experts on the field agreed on the need to 
revise the ACCP/SCCM definitions referred to above, no superior alternatives could be identified [3], 
which made the original definitions overall still valid until the conduct of this study. 
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Table 1. Definition criteria for sepsis-associated conditions 
Condition Definition criteria 
Systemic inflammatory 
response syndrome (SIRS) 
Presence of two or more of the following conditions: 
• Body temperature < 36°C or > 38°C 
• Heart rate > 90 bpm 
• Respiratory rate > 20/min or PaCO2 < 32 mmHg 
• WBC < 4000 cells/mm3, > 12000 cells/mm3 or  
> 10% immature forms 
Sepsis SIRS as response to an infection. 
Severe sepsis Sepsis associated with organ dysfunction, hypoperfusion or hypotension. 
Septic shock 
Sepsis with hypotension, despite adequate fluid resuscitation, along with 
the presence of perfusion abnormalities. 
Multiple organ dysfunction 
syndrome (MODS) 
Presence of altered organ function in an acutely ill patient such that 
homeostasis cannot be maintained without intervention. 
Adapted from 1992 ACCP/SCCM Consensus Conference definitions [2]. 
 
 
In 2016, the third international consensus definitions for sepsis and septic shock (Sepsis-3) [4] were 
published, focusing hereby on organ dysfunction accompanying suspected or proven infection rather than 
the clinical SIRS criteria used before. According to the authors, identification of sepsis by the old criteria 
was of poor sensitivity and specificity. 
It is stated that the inadequate focus on inflammation and the common model of a continuum from local 
infection to non-complicated sepsis, which is proceeding further to severe sepsis (characterized by organ 
failure) and subsequently septic shock, are out of date [4].  
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1.1.3. Epidemiology 
Sepsis, and in particular severe sepsis and septic shock, are still associated with high fatality and rising 
incidence. In the United States (US), they are the leading cause for death in critically ill patients [5], 
accounting for about as many annual deaths as acute myocardial infarction [6]. While sepsis is associated 
with a mortality of about 10 – 20 %, in severe sepsis this number is more than doubled (20 – 50 %). In 
septic shock it increases further to 40 – 80 %  [1]. In the late 20th century, the incidence of sepsis annually 
increased by 8.7 % in the US, peaking in a total incidence of 240.4 per 100,000 population in 2000. Even 
though the total in-hospital mortality decreased from 27.8 % to 17.9 % in the same period of time, the total 
number of deaths continued to rise due to the increase in incidence [7]. The incidence of severe sepsis in 
first world countries is reported to be approximately 50 – 100 per 100,000 population [8], thus being three 
to four times lower than the incidence of sepsis [7]. Both severe sepsis and septic shock have occurrence 
rates in intensive care units (ICUs) of about ten percent [6, 9], debiting the health care system an annual 
$16.7 billion in the US alone [6]. There is by far less data available concerning epidemiology of sepsis in 
third world countries, but since it is generally acknowledged that infectious diseases - which are the 
inevitable cause for sepsis - play an even greater role in developing countries, one can only presume that 
sepsis might be of similar or even greater importance in the third world [1]. 
 
1.1.4. Risk factors 
An individual person’s risk to develop sepsis is affected by a multitude of patient-specific factors and the 
most important one seems to be age. While sepsis incidence showed to be 0.2/1000 in children, it 
increased more than a hundredfold in patients over the age of 85 years (26.2/1000) [6]. But also certain 
ethnic groups displayed an elevated risk to develop sepsis, with relative risks of about 1.9 as compared to 
Caucasians [7]. Furthermore, the male sex seems to be a predisposing factor, with a relative risk of 1.28 
as compared to females [7]. Apart from that, certain medical conditions significantly raise one’s probability 
to contract sepsis, most of which seem to impair the immune system. Diseases like diabetes mellitus, 
cancer or an infection with the human immunodeficiency virus (HIV) should be named in the first place in 
that context [1]. 
 
1.1.5. Causative pathogens 
Since it was first assumed that lipopolysaccharide (LPS) played a crucial role in sepsis pathogenesis, 
gram-negative bacteria were originally blamed to be responsible for most of the sepsis cases, which was 
in fact confirmed by some studies [1, 10]. Recent studies, however, came up with the finding that gram-
positive bacteria in these days are outnumbering gram-negative bacteria in originating sepsis, with 52.1 %  
of US cases in 2000 being gram-positive sepsis compared to 37.6 % of cases caused by gram-negative 
microorganisms [7]. Apart from these, viral and fungal organisms could be identified as possible causative 
organisms for sepsis [1], the latter of which accounted for 4.6 % of sepsis-cases, constituting an increase 
of 207 % in a period of 20 years [7]. 
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1.1.6. Therapy 
1.1.6.1. Causal therapy 
Nowadays, the therapy of severe sepsis and septic shock can be roughly viewed as two-pronged: first, 
there is the crucial need for causal anti-infective therapy, which initially needs to cover a broad spectrum 
including all possible pathogens for the particular site of infection and should be administered as early as 
possible, directly after harvesting blood cultures [11]. As Kumar et al. could show in 2006, within the first 
six hours after the onset of hypotension, each hour of delay in the administration of antimicrobial therapy 
accounted for a mean decrease of 7.6 % in survival rate (Figure 1) [12]. If possible, there should be 
additional surgical or interventional infectious focus control in order to reduce the pathogen-load of the 
exposed body. 
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1.1.6.2. Supportive and adjunctive therapy 
The second mandatory component of effective sepsis therapy is the support of the patient’s vital functions, 
if necessary. Mechanical ventilation is often required, and in case of septic shock a hemodynamic therapy 
consisting of extensive fluid resuscitation and the administration of inotropic or vasopressor drugs is 
needed. In case of renal failure, the initiation of temporary renal replacement therapy (RRT) may be 
necessary. Patients may require prophylactic means (i.e. deep vein thrombosis prophylaxis, stress ulcer 
prophylaxis), the administration of blood products, hydrocortisone (HC), bicarbonate, analgesic or sedative 
agents, enteral or parenteral nutrition and blood glucose management via the adapted infusion of glucose 
and insulin in the critical phase of their disease. Moreover, a surgical approach may be required, 
depending on the individual case [11, 13]. 
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1.2. The immune system 
1.2.1. Physiology 
Crucial to the understanding of sepsis pathogenesis is the knowledge of the human immune system. In 
general, it can be divided into an innate (nonspecific) and acquired (specific) part, although both systems 
are strongly interacting by enhancing or modulating each other’s responses. 
 
1.2.1.1. Innate immune system 
The innate immune system is composed of a cellular as well as a humoral pathway, the first of which is 
predominantly represented by neutrophils, macrophages and natural killer cells, whilst the latter consists 
of antimicrobial substances, such as components of the complement system, which are released into the 
blood and interstitial fluids. In simplified terms, the innate immune system divides the world into the 
harmless “self” and the potentially dangerous “non-self”, dependent on physical structure. One main clue 
for the decision whether to classify a certain antigen as self or non-self is the recognition of particular 
carbohydrates, lipids, proteins or deoxyribonucleic acid (DNA) structures, which frequently occur among 
microbial invaders. For instance, the Cluster of Differentiation (CD) 14 cell surface protein on 
macrophages serves the purpose of identifying LPS, which is a very common component of the gram-
negative bacterial cell wall and thus indicative of bacterial infection when appearing in human bodily fluids 
[14]. 
 
1.2.1.2. Acquired immune system 
Besides the nonspecific innate immune system, the body is equipped with the more specific acquired 
immune system. Similar to the innate immune system, the acquired immune system also relies on cellular 
as well as humoral components. It is mainly mediated by lymphocytes, which can be divided, depending 
on the site of their maturation (indicated in brackets hereafter), in B-lymphocytes (bone marrow), which 
are responsible for the humoral part by secreting immunoglobulins, and T-lymphocytes (thymus), which 
mediate the cellular response to pathogens. T cells can be further divided into cytotoxic CD8+ cells, which 
kill their target cells by secreting lytic substances or by inducing apoptosis via the Fas ligand pathway, and 
CD4+ helper T cells (TH). The latter can be even further divided into two different main types of effector 
cells, TH1 and TH2. While the main purpose of TH1 cells has long been thought to be promoting cellular 
immune response by activating macrophages, natural killer cells and neutrophils, TH2 cells were 
considered to be in charge of stimulating the B-cell mediated specific humoral immunity [15, 16]. 
Communication between immune cells for the most part is performed via the release of cytokines, which 
can be viewed as messengers between cells. Leukocytes can activate or inhibit their surrounding cells by 
releasing cytokines in a paracrine fashion, or even affect themselves by using cytokines in an autocrine 
fashion. When having a closer look at the signature cytokines of both TH1 and TH2 cells, it becomes 
apparent that besides affecting different effector cells and thus the different paths of the immune system, 
their main effect on the inflammatory response seems to be contrary. While TH1 cells mainly produce 
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cytokines like interferon (IFN)-γ, interleukin (IL)-2 and tumor necrosis factor (TNF)-α, all of which recruit 
and activate inflammatory leukocytes and thus have pro-inflammatory effects, three of the most important 
cytokines typically released by TH2 cells, namely IL-4, IL-10 and IL-13, exert anti-inflammatory effects [16]. 
 
1.2.1.3. Processes occurring during infections 
In case of an infection, pathogens like bacteria, viruses or fungi enter a sterile site in the human body and 
are detected and phagocytosed by components of the innate immune system. Simultaneously, after 
recognizing particular structural patterns of the invading microorganisms, so-called pathogen-associated 
molecular patterns (PAMPs), the innate immune system alerts the host of the infection by secreting 
cytokines. These on the one hand increase the innate immune response by recruiting more leukocytes to 
the site of infection and, on the other hand, activate the adaptive immune system in a very complex way of 
interlinkage between the two parts of the immune system [17]. If the pathogen-load the body is exposed to 
can be handled by the host’s initial immune response, the inflammatory process is regulated and 
terminated by - amongst others - TH2 cells, and homeostasis of the body is gradually restored [16]. 
 
1.2.2. Pathophysiology of septic conditions 
1.2.2.1. Systemic inflammatory response syndrom 
In case of a persistent or particularly severe infection, the immune responses are potentiated by the 
activation of leukocytes by so-called damage-associated molecular patterns (DAMPs), which are 
molecular structures being released from damaged host tissue [18]. This process can advance into a 
vicious circle, with progressive inflammation entailing more tissue damage, and thus resulting in even 
more inflammation. Sepsis is present when the inflammatory process within the host increases to such a 
level that SIRS develops and the body reacts with systemic changes [17]. These can be neuroendocrine, 
hematopoietic, metabolic or hepatic changes [15]. If the infection persists and the body’s reaction 
exacerbates, organ dysfunction, tissue hypoperfusion or hypotension may occur, marking the emergence 
of severe sepsis. Septic shock is present when hypotension rises to such a level that, despite adequate 
intravenous fluid resuscitation, the administration of inotropic or vasopressor agents is required to 
maintain an adequate mean arterial blood pressure (MAP) [2]. These general changes to the body are 
partly mediated by an overwhelming amount of cytokines often termed as “cytokine-storm”, in which the 
cytokines not only affect surrounding cells in an autocrine and paracrine manner, but are released in such 
a quantity that they have an endocrine effect on all body tissues and contribute to the effects pointed out 
above [18]. Secondly, the exaggerated formation of molecules such as hydrogen peroxide, superoxide 
radical anion and hydroxyl radical - which are subsumed as reactive oxygen species (ROS) - is widely 
recognized to play a role in the genesis of the sepsis-associated sequelae named above, like 
cardiovascular insufficiency and tissue injury. These substances are mostly generated by macrophages 
and neutrophils [14, 19]. A third contributing factor seems to be the release of proteases and other 
antimicrobial peptides [17]. 
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1.2.2.2. Compensatory and mixed anti-inflammatory response syndrome 
Besides SIRS, which still is the hallmark sign of sepsis, another contrary condition in the progression of 
sepsis is described in the literature. It is associated with an inhibition of the immune system, resulting in a 
lack of response to pathogens, and goes by different names, such as compensatory anti-inflammatory 
response syndrome (CARS) or immune paralysis [18, 20, 21]. This condition causes a severe 
susceptibility to secondary infection and might be responsible for a significant number of deaths in the 
later phases of sepsis. There are different hypotheses concerning this immunosuppressive state. It is 
assumed that a shift from a TH1-dominated initial immune response resulting in excessive inflammation 
and, subsequently, SIRS, to a TH2-dominated anti-inflammatory state might contribute to the development 
of CARS [5]. Different works state that extensive lymphocyte apoptosis during sepsis progression seems 
to be, at least in part, responsible for the genesis of CARS [22]. Recent findings suggest that 
hyperinflammation and hypoinflammation are two concurrently developing processes in sepsis, terming it 
as mixed anti-inflammatory response syndrome (MARS) [20, 23]. There are numerous further theories 
concerning the pathophysiology of immunosuppression in sepsis, including impaired leukocyte recruitment 
and decreased cell surface protein expression [24]. After all, the exact pathophysiology of sepsis and the 
accompanying hyperinflammatory and immunosuppressive states are still poorly understood, despite 
great efforts in research on this topic. A better understanding of these conditions is needed to eventually 
make considerable therapeutic advances. 
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1.3. Goals of the work 
To the present day, there have been numerous approaches on modulating the patient’s immune response 
in sepsis, none of which has been promisingly successful in clinical trials until now [5]. The aim of this 
work was to investigate cellular leukocyte responsiveness of inpatients admitted to an ICU suffering from 
severe sepsis or septic shock. 
 The first main objective was to evaluate the patients’ initial immune function, determined shortly 
after the onset of severe sepsis or septic shock, respectively, in comparison to a healthy control group. 
We hypothesized that there would be general immunosuppression in patients and intended to further 
quantify and distinguish this condition. 
 Secondly, we targeted to identify different parameters correlating with the level of immune 
dysfunction, such as demographic, biometric, clinical, immunological, and outcome-parameters. 
 Thirdly, dependent on the findings in the items named above, we aimed at setting on possible 
hypotheses for pathophysiologic processes occurring during sepsis, thus contributing to a better 
understanding of sepsis pathogenesis. This study might constitute a small step towards future diagnostic 
and therapeutic strategies, as currently no single biomarker is available for clinical use in the assessment 
of immune dysfunction [24]. 
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2. Materials and methods 
2.1. Study design 
2.1.1. SISPCT 
Patients were enrolled in our study as participants of a superordinate study designed as a prospective, 
randomized, multicentric clinical trial named “Placebo Controlled Trial of Sodium Selenite and 
Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis” (SISPCT; clinicaltrials.gov identifier: 
NCT00832039 [25]) designated to enrol 1.180 patients in various German ICUs. Aim of this trial was to 
investigate the influence of sodium selenite infusions (randomized, double-blind) and Procalcitonin (PCT) 
guided causal therapy (randomized, open-label) on the survival and various secondary outcome measures 
of patients suffering from severe sepsis or septic shock. Patient recruitment for SISPCT was started in 
November 2009 and ended in March 2013 [25]. 
 
2.1.1.1. Inclusion criteria 
In order to qualify for study enrolment, patients had to meet the criteria for either severe sepsis or septic 
shock according to the ACCP/SCCM definitions valid at the time of study conduct [2]. First, there had to 
be a clinically suspected or microbiologically proven infection in combination with two or more of the SIRS-
criteria, indicating the presence of sepsis (Table 1). As opposed to the original ACCP/SCCM definitions as 
seen in Table 1, all interval boundaries (e.g. 38°C, 90 bpm, etc.) were included to fulfil the criteria. 
Moreover, the necessity of mechanical ventilation alone qualified to fulfil the respiratory criterion, besides 
an elevated respiratory rate and a decreased PaCO2. In addition, in order to meet severe sepsis or septic 
shock definitions, one or more of the following had to be present: acute encephalopathy, 
thrombocytopenia, renal dysfunction, metabolic acidosis, arterial hypoxemia, arterial hypotension or septic 
shock (Table 2). Patients had to be enrolled within a time frame of 24 hours after onset of severe sepsis or 
septic shock. 
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Table 2. SISPCT criteria for severe sepsis and septic shock 
Condition Organ dysfunction Definition criteria 
Severe sepsis 
Acute encephalopathy 
Reduced vigilance, anxiety, disorientation, without 
interference by psychotropic agents. 
Thrombocytopenia 
Thrombocytes ≤ 100,000/µl or decrease in thrombocytes > 
30% within 24 hours without being caused by blood loss. 
Renal dysfunction 
Urinary output ≤ 0.5 ml/kg/h despite sufficient fluid 
substitution and/or a rise of serum creatinine ≥ 2 x above 
reference range. 
Metabolic acidosis 
Base excess ≤ -5 mmol/l and/or plasma lactate 
concentration ≥ 1.5 x above reference range. 
Arterial hypoxemia 
PaO2 < 10 kPa (75 mmHg) without oxygen administration 
or PaO2/FiO2 ≤ 33 kPa (250 mmHg) under oxygen 
administration without presence of a cardiac or pulmonary 
disease accountable for hypoxemia. 
Arterial hypotension 
Systolic blood pressure ≤ 90 mmHg or MAP ≤ 70 mmHg 
for at least 1 hour despite sufficient fluid administration 
under absence of other causes for circulatory shock. 
Septic shock 
Systolic blood pressure ≤ 90 mmHg or MAP ≤ 70 mmHg 
for at least 2 hours despite sufficient fluid administration or 
necessity of vasopressor agents to establish a systolic 
blood pressure ≥ 90 mmHg or MAP ≥ 70 mmHg under 
absence of other causes for circulatory shock. 
As part of the SISPCT inclusion criteria, one or more of these criteria had to be present in addition to the presence of 
sepsis to allow for patient enrolment. PaO2: Arterial partial pressure of oxygen, kPa: Kilopascal, mmHg: Millimetres of 
mercury, FiO2: Fraction of inspired oxygen, MAP: Mean arterial pressure. 
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2.1.1.2. Exclusion criteria 
Patients who met one or more of the following exclusion criteria at screening could not be enrolled: 
pregnancy, breastfeeding period, selenium intoxication, an infection in which guidelines suggest a long-
term antimicrobial therapy, therapy limitation or termination, infaust prognosis, severely immunologically 
compromised patients with CD4+ counts < 200/mm3 or neutrophils < 500/mm3 or pharmacological 
immunosuppression in status post solid organ transplantation, participation in another clinical trial within 
the last 30 days, current participation in another research project, earlier participation in SISPCT or a 
personal relation to the principal investigator. 
 
2.1.1.3. Informed consent procedure 
After positive patient screening suggesting patient enrolment, either an informed consent signed by the 
patient or, in case of impaired legal competence at that time - e.g. due to acute encephalopathy or 
analgesic sedation - a surrogate confirmation had to be present in order to be able to enrol the patient. 
The surrogate confirmation could either be the signed consent of a patient’s medical representative or, if 
none was available, a written declaration of a medical consultant from a different medical subject allowing 
patient enrolment. In case of patients having been enrolled based on a medical consultant’s declaration, 
an informed patient’s or medical representative’s consent or refusal had to be obtained within a few days 
after study enrolment. In case of subsequent refusal, the patient concerned was excluded from the study 
immediately and no further follow-up was performed.  
 
2.1.1.4. SISPCT study arms 
Directly after study enrolment patients received a bolus, which was administered over the course of 20 
minutes via a central venous catheter. It consisted of either 1000 µg of selenium, dissolved as sodium 
selenite pentahydrate (selenase® T pro injectione, biosyn Arzneimittel GmbH, Fellbach, Germany) in 
aqueous 0,9 % sodium chloride solution (50 ml total volume) or the same amount of placebo in the form of 
50 ml of aqueous 0,9 % sodium chloride solution. Subsequently, patients received a continuous infusion of 
sodium selenite pentahydrate, dissolved as described above, at a rate of 1000 µg of selenium per 24 
hours, or the same volume of placebo, respectively. Assignment to either of these two study arms took 
place in a randomized, double-blinded fashion. The continuous infusion was administered for the duration 
of the patient’s stay on ICU, but maximum for 21 days. 
Independently from this, all patients were assigned to either the PCT guided causal therapy arm or the 
control arm. In the PCT guided arm, causal therapy, i.e. antimicrobial therapy, interventions for focus 
control and diagnostic measures were supposed to be directed according to a certain algorithm based on 
plasma PCT levels on certain days after study enrolment. For the control group, no plasma PCT levels 
were determined and no therapeutic suggestions were made. Assignment to either of these two arms was 
performed in a randomized, open-label fashion.  
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2.1.1.5. Study procedures 
During the length of ICU stay, but maximum for 21 days, clinical, laboratory and therapeutic parameters 
were recorded in detail. Additional follow-ups were scheduled for day 28 and day 90 after study enrolment. 
During stay on ICU, blood samples were taken on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14 and 21 for later 
analysis. Naturally, all study interventions and inquiries were implemented in addition to the usual critical 
care treatment necessary. 
 
2.1.2. Immune function substudy 
From June 2011 through February 2013 we recruited a total of 76 patients for the additional assessment 
of their immune function, besides their regular participation in SISPCT (Amendment of ethical approval: 
Eudra-CT-Nr. 2007-004333-42). All of these patients were recruited in one particular of SISPCT’s trial 
sites: Ludwig-Maximilian University of Munich, Klinikum der Universität München, Klinikum Großhadern, 
Department of Anaesthesiology, on the ICUs “H2”, “H3b” and “I3”, respectively. Inclusion and exclusion 
criteria were identical to those of SISPCT, whereas the different SISPCT study arms were not considered 
dissociatedly in our study due to the small sample size and the blood withdrawal taking place before 
administration of the study drugs. In the following, “immune study” shall refer to the tests on immune 
function, whereas “SISPCT” represents the multicentre trial described above. Complementary to the 
patient population, we recruited 11 age- and sex-matched healthy volunteers (HV) as a control group 
between September 2012 and December 2012 to participate in the study after giving signed informed 
consent. In regard to gender distribution, age and body mass index, the control group and patient 
collective did not differ significantly (Table 3). 
 
 
 
 
Table 3. Demographic and biometric characteristics of patients versus control group 
Variable Patient Population Control group 
N 76 11 
Female, n (%) 35 (46 %) 3 (27 %) 
Age (years) [IQR] 65 [50 – 73] 54 [48 – 64] 
Body mass index (kg/m
2
) [IQR] 26 [23 – 32] 25 [23 – 29] 
No significant group differences were detected regarding gender distribution (Fisher’s exact test, p = 0,335), age 
(Pearson’s chi-squared test, p = 0,249) and body mass index (Pearson’s chi-squared test, p = 0,248). 
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2.2. Laboratory methods 
2.2.1. Blood sample obtainment 
Subsequent to patient enrolment (Day 0) or, in case of the control group, at a time of subjective physical 
well-being, 9 ml of blood was withdrawn into a lithium-heparinized tube (S-Monovette® 9 ml, Lithium-
Heparin, 92x16 mm, Sarstedt AG & Co., Nümbrecht, Germany). For patient blood sample obtainment, a 
pre-existent arterial catheter or - if none was available at the time - a central venous access was used. In 
case of the control group, single peripheral vein puncture was performed. 
 
2.2.2. Whole blood stimulation 
Subsequently, 400 µl of lithium-heparinized whole blood was transferred under aseptic conditions into 
each tube prefilled with an equal volume (400 µl) of DMEM (Dulbecco´s Modified Eagle’s Medium Nutrient 
Mixture F-12 HAM, Sigma-Aldrich, Steinheim, Germany) and the different stimulants (800 µl total assay 
volume). The assay tubes contained DMEM only or DMEM and either a bacterial antigen mixture 
(Bacteria) containing diphteria-, tetanus- and pertussis-toxoid (all 3 combined in 1% Boostrix®, 
GlaxoSmithKline, Munich, Germany), or fungal antigen mixture (Fungi) containing candida-lysate (10 
µg/ml, Allergopharma, Reinbeck, Germany) and trichophyton-lysate (10 µg/ml, Allergopharma, Reinbeck, 
Germany) or Pokeweed mitogen (PWM) (5 µg/ml, Sigma-Aldrich, Steinheim, Germany) as positive control. 
For specific lymphocyte stimulation, we chose the bacterial antigens named above, because they 
constitute some of the antigens used in standard vaccinations recommended by the public authorities [26]. 
The fungal species employed are characterized by an ubiquitous occurrence in the environment. It can be 
assumed that almost all patients and HVs had been exposed to the chosen antigens prior to study 
participation and thus were equipped with specific memory cells, enabling them to exert a prompt specific 
immune response. PWM acts as a strong “polyclonal” activator, inducing mitosis in T as well as B 
lymphocytes in a maximal but non-receptor specific way [27, 28]. 
Additionally, there were three more stimulation solutions kindly provided by the National Aeronautics and 
Space Administration (NASA) (Washington, District of Columbia, USA), which were included at a later 
time, beginning with the 19th study patient. In case of these reagents, 150 µl of whole blood was 
transferred under aseptic conditions into each tube prefilled with 1 ml of Roswell Park Memorial Institute 
medium (RPMI) containing LPS (10 µg/ml, Sigma-Aldrich, St. Louis, Missouri, USA), phorbol 12-myristate 
13-acetate and ionomycin (PMA, 10 ng/ml PMA and 2 µg/ml ionomycin, both from Sigma-Aldrich, St. 
Louis, Missouri, USA) or human T-activator CD3/CD28 (CD3/28; 0.125 µg/ml anti-CD3 and 0.25 µg/ml 
anti-CD28; both from Becton Dickinson, Franklin Lakes, New Jersey, USA). LPS functions as an activator 
of cells of the innate immune system via the CD14 cell surface receptor and Toll like receptor (TLR) 4 
signaling cascade [29]. PMA is a potent biologic stimulus [30] whose effect is increased when applied in 
conjunction with ionomycin. It serves as an unspecific activator of Protein kinase C (PKC) [31] and thus 
affects multiple cell types. Besides serving as a mitogen for T lymphocytes [32], it seems to have pro-
inflammatory effects [30] and thus causes morphologic changes as well as an increased degranulation, 
ROS-generation, and phagocytosis in innate immune cells [33-35]. CD3/28 is a solution intended for 
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physiological activation of the CD3 antigen, which constitutes the human T cell receptor, and CD28, which 
is a receptor exerting costimulatory effects on the human T cell receptor [36]. These two receptors seem 
to occur only in T cells [37], which makes CD3/28 a reagent stimulating exclusively T lymphocytes. 
 
2.2.3. Sample processing and analysis 
The assay tubes were incubated altogether for 48h at 37°C. After 48 hours, the following were transferred 
into Eppendorf tubes and immediately frozen at -80°C for future cytokine analyses: 150 µl of supernatant 
plasma in case of tubes containing just DMEM, bacterial / fungal antigens or PWM, or 200 µl of 
supernatant plasma in case of tubes containing LPS, PMA and CD3/28, respectively. By rarefying these 
small supernatant volumes significant dilution effects could be minimized. Frozen supernatants were 
measured in a blinded fashion after thawing.  
In case of tubes containing just DMEM, bacterial / fungal antigens or PWM the concentrations of the 
prototypic TH1 cytokines IL-2, IFN-γ and TNF-α were analyzed by Luminex xMAP® technology (Bioplex®) 
with commercially available reagents from BioRad-Laboratories Inc. (California, USA) according to the 
manufacturer’s guidelines [38]. Data was analyzed using Bioplex®-Software. 
Cytometric bead array (CBA) assessments were performed on supernatants from the tubes containing 
RPMI and LPS, PMA or CD3/28. CBA assays simultaneously measure multiple analytes using antibody-
coated bead populations with unique fluorescence intensities. For the CD3/28 and PMA cultures, a TH1/ 
TH2 CBA assessment (Becton Dickinson, Human Th1/Th2 Cytokine Kit, Catalogue Number 550749) that 
analyzed secreted IFN-γ, TNF-α, IL-10, IL-5, IL-4 and IL-2 was performed. For LPS cultures, an 
inflammatory CBA assay (Becton Dickinson, Human Inflammatory Cytokines Kit, Catalogue Number 
551811) was performed, which assessed secreted TNF-α, IL-10, IL-6, IL-1β, IL-8, and IL-12. All CBA 
assays were performed according to the manufacturer’s instructions. Samples were batch-analyzed and a 
Beckman Coulter flow cytometer was configured to resolve all bead populations. Data were recorded as 
mean fluorescence intensity (MFI) and subsequently converted to pg/ml concentrations by plotting the 
subject MFI data against the MFI values established from a standard curve, according to Crucian et al. 
[39]. 
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2.3. Electronic data processing 
2.3.1. Data recording 
Data recording was performed in an anonymized way using IBM SPSS® Statistics V21 (IBM Corp., New 
York City, New York, USA). We defined the time span of 24 hours before study enrolment as “Baseline” 
and the time from study enrolment to 7 a.m. the next day as “Day 0”. The following days were 
consecutively numbered, with each day beginning and ending at 7 a.m. In addition to the acquisition of 
demographic, biometric, anamnestic, clinical and laboratory data and therapeutic procedures in each 
individual patient, the common severity of disease classification systems Simplified Acute Physiology 
Score (SAPS II) [40] and Acute Physiology And Chronic Health Evaluation II (APACHE II) [41] were 
calculated for the Baseline period. Cytokine data were included in the database after determination. In 
case of cytokine concentration values below the lower detection limit, we used the value of the lower 
detection limit in order to be able to perform statistic calculations. 
 
2.3.2. Statistical analysis and plotting 
Data was statistically analyzed and graphically plotted using IBM SPSS® Statistics as well as SigmaPlot 
12.5 (Systat Software Inc., San Jose, California, USA). 
In order not to distort raw data, no outlier analysis was performed. After testing for normal distribution 
using One-Sample Kolmogorov-Smirnov test or Shapiro-Wilk test, data was analyzed using Student’s T-
test, Kruskal-Wallis one-way analysis of variance (ANOVA) on ranks or Mann-Whitney Rank Sum Test, 
dependent on presence of normal distribution. Correlation analyses were performed using Pearson’s 
correlation coefficient or Spearman rank-order correlation coefficient, as appropriate. Normally distributed 
continuous data is given as mean ± standard deviation (SD), not normally distributed data is given as 
median [interquartile range (IQR)]. All p-values were calculated in a two-sided manner and statistical 
significance was set at an α-value of 0,05. 
For better comparability of not normally distributed data, variable values were divided into specific groups 
(indicated in the individual charts) or four quartile groups, with the 25th, 50th and 75th percentile 
representing the cutoff values for group allocation. In boxplots, boxes show the median and IQR, whiskers 
represent the 10th and 90th percentile. 
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3. Results 
3.1. Study population 
76 Patients were included in the study, seven of which later refused consent or were lost to follow up 
within the follow up period of 90 days. All patients experienced onset of severe sepsis (8 %) or septic 
shock (92 %) within 24 hours prior to study enrolment (Table 4). 
 
Table 4. Sepsis and admission type characteristics 
 Total n = 76 Admission type 
 Severe sepsis Septic shock Medical 
Non-scheduled 
surgical 
Scheduled 
surgical 
N (%) 6 (8 %) 70 (92 %) 41 (54 %) 27 (36 %) 8 (11 %) 
 
96 % of patients were on 
antimicrobial therapy at the time of 
study enrolment. Most frequent focus 
localization was the respiratory tract 
(53 %), followed by the abdomen (19 
%) and urinary tract (7 %). Detection 
of pathogens causing sepsis could be 
accomplished in 51 % of cases, 53 % 
of which were gram-negative 
bacterial, as compared with 38 % of 
gram-positive bacterial and 8 % of 
viral sepsis (Table 5). Within the 
study population, median Baseline 
SAPS II was 67, APACHE II 
averaged 27 and - for the main part 
due to frequent analgosedation - 
patients attained a median of 3 on the 
Glasgow Coma Scale (GCS). 
Mechanical ventilation was performed 
in 83 % of patients. 95 % of patients 
were on inotropic or vasopressor 
agents at the time of study enrolment, 
namely norepinephrine solely or in  
Table 5. Microbiological and infection characteristics 
Variable N (%) 
Microbiologically proven infection 39 (51 %) 
Gram-positive bacterial 15 (38 %)a 
Gram-negative bacterial 21 (54 %)a 
Viral 3 (8 %)a 
Focus of infection  
Respiratory tract 40 (53 %) 
Abdomen 14 (19 %) 
Urinary tract 5 (7 %) 
Other 17 (22 %) 
Baseline antiinfective therapy
b 73 (96 %) 
a Percentages given with reference to the number of microbiologically 
proven infections.   b Number of patients who received antimicrobial 
substances within 24 hours prior to study enrolment. 
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combination with vasopressin (31 %), 
epinephrine (27 %) and/or dobutamine (7 %) 
(Table 6). Median length of ICU stay was 11 
days. 35 % of patients required renal 
replacement therapy while on ICU and 12 % 
of patients deceased during ICU stay. 90-day 
mortality was 20 % (Table 7). On average, 
patients presented a considerable rise in 
infection parameters, a hematopoietic left 
shift, relative lymphopenia and relative 
granulocytosis, accompanied by moderate 
anemia and renal impairment. For a detailed 
cross section on Baseline laboratory values 
see Table 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Baseline medical status 
SAPS II 67 [52 – 78] 
APACHE II 27 ± 8 
Glasgow coma score 3 [3 – 14] 
Norepinephrine administered 70 (95 %)a,b 
     Maximum norepinephrine dose (mg/h) 1,9 [0,9 – 3,0] 
Vasopressin administered 23 (31 %)a 
Epinephrine administered 20 (27 %)a 
Dobutamine administered 5 (7 %)a 
Mechanical ventilation 63 (83 %) 
     Non-invasive 10 (13 %) 
     Invasive 53 (70 %) 
Minimum PaO2/FiO2 118 [76 – 201] 
Minimum arterial pH 7,29 ± 0,11 
Characteristics for the patient population’s medical status 
within 24 hours prior to study enrolment. Values are given as 
mean ± SD, median [IQR] or n (%). a Two missing values. Total 
n = 74. b Two patients with severe sepsis received 
norepinephrine status post non-scheduled abdominal surgery, 
but did not qualify for septic shock. SAPS II: Simplified Acute 
Physiology Score; APACHE II: Acute Physiology and Chronic 
Health Evaluation; PaO2: arterial partial pressure of oxygen; 
FiO2: fraction of inspired oxygen. 
Table 7. Outcome characteristics 
Renal replacement therapy
a
, n (%) 26 (35 %) 
Length of stay on ICU (days) [IQR] 11 [5 – 21] 
ICU mortality, n (%) 8 (12 %) 
90-day mortality, n (%) 14 (20 %) 
a Initiation of renal replacement therapy during stay on ICU. 
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Table 8. Baseline laboratory values  
Category Variable (unit) Value n 
Differential blood 
count
a 
Hemoglobin (g/dl) 10.1 [9,1 – 12,1] 65 
Hematocrit (%) 30,0 [27,2 – 33,2] 51 
Platelets (G/l) 192 ± 98 68 
White blood count (G/l) 14.6 ± 10.6 65 
Segmented neutrophils (%) 85 [72 – 91] 18 
Banded neutrophils (%) 13.8 ± 10.6 8 
Monocytes (%) 5.9 ± 3.6 18 
Lymphocytes (%) 6,5 [3,0 – 9,0] 20 
Clinical 
chemistry
b 
Sodium (mmol/l) 140 ± 5 71 
Potassium (mmol/l) 4,2 ± 0,8 69 
Glucose (mg/dl) 151 ± 55 69 
Creatinine (mg/dl) 1,4 [1,0 – 2,4] 68 
Total bilirubin (mg/dl) 1,3 [0,9 – 2,2] 67 
GOT/ASAT (U/l) 51 [27 – 99] 62 
GPT/ALAT (U/l) 32 [20 – 57] 66 
Lipase (U/l) 22 [7 – 44] 50 
C-reactive protein (mg/dl) 17,9 [10,7 – 27,8] 68 
Interleukin 6 (pg/ml) 1248 [252 – 4673] 62 
Procalcitonin (ng/ml) 6,6 [1,9 – 21,3] 51 
Coagulation
c 
INR 1,2 [1,1 – 1,5] 73 
aPTT (sec) 30 [26 – 38] 72 
Fibrinogen (mg/dl) 563 ± 230 58 
Values were determined from a whole blood, b blood serum or c blood plasma.  Dependent on 
the presence of normal distribution, values are given either as mean ± SD or as median 
[IQR], respectively. GOT: glutamic oxaloacetic transaminase; ASAT: aspartat 
aminotransferase; GPT: glutamate-pyruvate transaminase; ALAT: alanine aminotransferase; 
INR: International normalized ratio; aPTT: activated partial thromboplastin time. 
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3.2.  SISPCT  
Regarding the SISPCT endpoints “selenium vs placebo” as well as “PCT guided anti-infectious therapy vs 
no PCT guidance”, neither our dataset (data not shown) nor the SISPCT trial showed any significant 
differences in 28-day mortality in either of the study arms. PCT guidance resulted in a reduction of 
antimicrobial exposure - which served as a secondary endpoint - of 4,5 % per 1000 patient years, 
however. Results of the SISPCT trial were published in the Journal of the American Medical Association 
(JAMA) Internal Medicine in 07/2016 [42]. 
With regard to the cytokine release data acquired at Baseline, before implementation of the study 
interventions, no significant differences regarding the study arms could be detected (data not shown). The 
distribution of the patients in our database to the four study arms was about equal, lacking statistical 
significant divergence (selenium, PCT guidance n = 20, 26,3 %; selenium, no PCT guidance n = 20, 26,3 
%; placebo, PCT guidance n = 18, 23,7 %; placebo, no PCT guidance n = 18, 23,7 %; total n = 76). Due to 
the small sample size in our database and the lack of relevant significant effects of both aspects examined 
in the SISPCT intervention study, we did not take the different study arms into consideration in our further 
analyses.  
 
 
3.3. Initial immune function 
All data used in this chapter refers to the situation at study enrolment and incorporates only values 
gathered in the defined study periods Baseline or Day 0, respectively. 
 
3.3.1. Patients versus control group 
In comparison to the patients suffering from severe sepsis or septic shock (SS), a control group of 11 
persons matching the patient population in age, sex ratio and BMI (as shown in Table 3) were included in 
the study. By assessing concentrations of different cytokines in the supernatants of whole blood incubated 
with various stimulants, their cellular immune function was compared to the patients’ immune function at 
study enrolment. Results are displayed in Figure 2 and Figure 3. 
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First of all, it is notable that in most cases (26 out of 30), significantly lower cytokine concentrations were 
found in the patient collective as compared to the healthy control group. Differences were in fact highly 
significant in the majority of cases (p < 0,001 in 16 and p < 0,01 in 7 out of 30 tested assays). These 
results indicate a severe, general cellular immune dysfunction which is already present shortly after the 
manifestation of severe sepsis or septic shock, respectively, and which doesn’t seem to be restricted to 
specific cell types, since stimulants and measured cytokines of all types are affected. Even in the 
unstimulated assay, the control group showed a higher cytokine secretion than the patients, which was 
statistically significant for IL-2 and IFN-γ (Figure 2). 
In detailed consideration of the results, it is remarkable that the assay stimulated with LPS, which fully 
addresses the innate immune system, showed the least significant results. Consistent with this, assays 
relying on a specific immune response were particularly affected by the suppression of cytokine release. 
After stimulation with bacterial or fungal antigen mixture, the release of the pro-inflammatory cytokines IL-
2 and IFN-γ - which is predominantly mediated by T-lymphocytes [43] and thus dependent on the specific 
immune system - showed to be on a very low level compared to the control group (Figure 2, altogether p < 
0,001). 
In case of IL-10, which represents a prototypic cytokine exerting anti-inflammatory actions, statistically 
significant group differences only occur in the CD3/28 assay, but on a rather low significance level (p < 
0,05). In the LPS and PMA assays, groups do not differ on a statistically significant level regarding IL-10 
release (Figure 3). It is noteworthy, however, that patients did not exceed the control group in release of 
anti-inflammatory cytokines in any of the assays tested.  
There is, however, a strong variability in the individual immune response, which occurs not only in the 
assays requiring prior antigen exposure and thus a specific immune response (namely the Bacteria and 
Fungi assays), but also is present in the assays using unspecific stimulants. This variability reaches 
dimensions of more than 103 under physiologic conditions (control group) and exceeds 105 in the patient 
collective (Figure 2, Figure 3). As a result, in some assays (i.e. Basal, LPS, PMA, cf. Figure 2 and Figure 
3) single patients exceed the control group in their cytokine response, whereas the majority of the patient 
collective undercuts the control group’s values in all assays.  
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3.3.2. Subcohort analyses 
Examining the data for inter-patient variations in cytokine release, we made one general finding: in assays 
mostly addressing specific immunity (Bacteria, Fungi, CD3/28), significant discrimination between patients 
was not possible. This was due to the fact that, in these assays, a considerable fraction of the patients 
showed cytokine concentrations below the lower detection limit, which made a detailed analysis 
impossible (data not shown). This issue also affected the assays completely or partly relying on innate 
immunity (PWM, PMA1, LPS), but to a lower degree, which made the detection of correlations possible in 
these assays. In order to maintain consistency and comparability between different graphs and 
calculations, we restricted our considerations for the most part to two read-outs: the concentrations of IL-
1β in LPS-stimulated whole blood and of TNF-α in PWM-stimulated whole blood, respectively. 
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3.3.2.1. White blood count 
On the one hand, leukocytes are the cells that are responsible for releasing cytokines, so one could 
possibly assume that the WBC might show a positive correlation with cytokine release. But on the other 
hand, however, the WBC is an important inflammation marker: both ends of the spectrum, leukopenia as 
well as leukocytosis, can indicate inflammatory processes and thus both conditions represent one of the 
four SIRS criteria [2] (cf. Table 1). After calculating Spearman’s rank correlation coefficients for WBC 
versus cytokine release in Day 0 stimulated whole blood, correlations significant on the .95 significance 
level could only be found in three out of 30 tested read-outs in a two-tailed test. In two out of the three 
cases, a negative correlation was found, while the remaining case showed a positive correlation (data not 
shown). This indicates that, considering the entirety of results, no stringent linear correlation is present. 
Figure 4.A shows a scatterplot for patients’ WBC versus IL-1β release after stimulation with LPS at day 0. 
It suggests a non-linear correlation with leukopenic and severely leukocytotic patients showing the faintest 
IL-1β release. Figure 4.B shows the corresponding boxplot after allocation of patients to four groups 
(leukopenia, normal leukocytes, moderate leukocytosis, severe leukocytosis). It shows that the group of 
patients with moderate leukocytosis (leukocytes 12,1 – 20 G/l) had the best immune response, whereas 
the leukopenic as well as the severely leukocytotic group showed a considerably impaired cytokine 
release. 
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3.3.2.2. Interleukin 6 serum level 
Interleukin 6 (IL-6) serves as a reliable inflammatory marker in modern critical care medicine and is 
characterized by a fast dynamic, with a biological half-life period of less than 6 hours [44]. It thus 
represents an early indicator of inflammatory processes. 
Figure 5.A shows a scatterplot for Baseline IL-6 determined in the blood serum versus IL-1β release after 
stimulation with LPS. A negative correlation becomes evident. For better statistical assessment of the 
underlying correlation, quartile groups were formed for IL-6 baseline values (Figure 5.B), proving the 
statistical significance of the formerly mentioned negative correlation. 
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Figure 6 shows the TNF-α release in both the unstimulated assay (Figure 6.A) as well as the assay 
stimulated with PWM (Figure 6.B) plotted against quartile groups for serum IL-6. While presenting the 
highest TNF-α concentration in the unstimulated assay, the group with the highest increase in serum IL-6 
shows a considerably impaired TNF-α secretion after stimulation with PWM. 
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3.3.2.3. Disease severity classification systems 
In order to determine possible correlations with disease severity, we used two disease severity 
classification systems which are commonly applied in critical care medicine – the Simplified Acute 
Physiology Score (SAPS II) and the Acute Physiology and Chronic Health Evaluation II (APACHE II). 
Each of these scores was calculated for the time span of 24 hours before study enrolment for any patient. 
If more than one value within that given time interval was documented for any variable, the value resulting 
in maximum score value was used for score calculation. 
The SAPS II was first described in 1993 and incorporates 17 parameters, which represent physiologic 
measurements, information about previous health conditions and admission type: Age, heart rate, systolic 
blood pressure, body temperature, GCS, the presence of mechanical ventilation or CPAP, PaO2, FiO2, 
urine output, blood urea nitrogen, serum sodium, serum potassium, serum bicarbonate, serum bilirubin, 
WBC, the presence of chronic diseases (metastatic cancer, hematologic malignancies, AIDS) and 
admission type (scheduled surgical, non-scheduled surgical, medical), resulting in a score between 0 and 
163. The SAPS II showed to be a good predictor of vital status at hospital discharge, independent from 
primary diagnosis [40]. We formed quartile groups for Baseline SAPS II score values for correlation with 
cytokine data. 
The APACHE II score was established in 1985 and incorporates the 16 parameters age, GCS, body 
temperature, mean arterial pressure, heart rate, respiratory rate, FiO2, PaO2, arterial pH, serum sodium, 
serum potassium, serum creatinine, the presence of acute renal failure, hematocrit, WBC and the 
presence of severe organ system dysfunction or immunodeficiency, resulting in a score between 0 and 71. 
APACHE II proved its ability to predict mortality in a highly significant way, taking into account that, in 
contrast to SAPS II, the type of principal diagnosis affects mortality rates [41]. We also formed quartile 
groups for Baseline APACHE II score values. 
In our dataset, correlation of SAPS II and APACHE II values with 90-day mortality showed a tendency 
towards a positive correlation, which was not statistically significant, though (data not shown). Figure 7 
shows SAPS II and APACHE II score values plotted against the release of TNF-α after stimulation with 
bacterial antigen mixture (Figure 7.A, 7.B) and PWM (Figure 7.C, 7.D). An increase in disease severity 
was associated with significantly impaired immune response both after bacterial antigen as well as after 
PWM stimulation. This finding applied to SAPS II as well as APACHE II scores. 
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3.3.2.4. Hydrocortisone administration 
In patients with refractory septic shock in which hemodynamic stability cannot be restored by both 
adequate fluid resuscitation and usage of vasopressors, it is recommended to consider the administration 
of corticosteroids at a dose of 200 - 300 mg of hydrocortisone per day [11, 13]. Since hydrocortisone has a 
dose dependent immunosuppressive effect, we excluded the patients having received minor doses of 
hydrocortisone. In our patient collective, 41 patients (54 %) received hydrocortisone at relevant doses of > 
50 mg at Day 0. We compared this group to the patients who were administered hydrocortisone at a dose 
of ≤ 50 mg (most of which in fact received no hydrocortisone at all) regarding cytokine release 
(hydrocortisone amount: hydrocortisone > 50mg: 243,9 ± 116,7 mg/24h, n = 41; hydrocortisone ≤ 50mg: 
1,8 ± 8,6 mg/24h, n = 35).  
Analysis of the two hydrocortisone groups revealed no significant differences in the complete blood count, 
though in the disease severity scores (hydrocortisone > 50mg: SAPS II = 73,3 ± 14,8, n = 41; 
hydrocortisone ≤ 50 mg: SAPS II = 56,3 ± 12,8, n = 33; hydrocortisone > 50 mg: APACHE II = 31,3 ± 6,8, 
n = 41; hydrocortisone ≤ 50 mg: APACHE II = 22,6 ± 7,7, n = 33). Patients who received hydrocortisone at 
a dose of more than 50 mg had significantly higher IL-6 levels compared to the low dose group 
(hydrocortisone > 50 mg: serum IL-6 = 31651 ± 95995 pg/ml, n = 33; hydrocortisone ≤ 50 mg: serum IL-6 
= 4581 ± 15787 pg/ml, n = 29; Mean ± SD; Mann-Whitney-U test, p = 0,016).  
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For the group of patients receiving > 50 mg of hydrocortisone, Figure 8 shows highly significant 
suppression of TNFα in the PWM assay (Figure 8.A, p < 0,001) and IL-1β release in the LPS assay 
(Figure 8.B, p < 0,01), respectively. This significant difference was present although the stimulated 
cytokine response in all septic patients was enormously reduced compared to healthy volunteers. 
 
 
 
3.3.2.5. Hypoxemia and hypoxia 
Recent findings describe an anti-inflammatory effect of tissue hypoxia, which is mediated by the 
Adenosine A2A-receptor. This effect might be useful in preventing inflammatory tissue damage, such as in 
inflammatory conditions affecting the lungs or liver [45, 46], but could, on the other hand, further enhance 
an existing immunosuppression. 
We divided the patient collective into groups of hypoxemic patients (PaO2 < 80 mmHg), normoxemic 
patients (PaO2 80 – 100 mmHg) and hyperoxemic patients (PaO2 > 100 mmHg). SAPS II and APACHE II 
showed similar scores irrespective of the three PaO2 groups (data not shown). Figure 9 shows correlations 
between PaO2 and cytokine release in the assays stimulated with PWM and LPS, respectively. In both 
assays, supernatant cytokine concentrations in the normoxemic group were significantly higher than those 
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in the hypoxemic group. The groups with higher oxygen tension only differed on a level that was 
statistically not significant.  
In contrast to hypoxemia, which is defined as a lack of oxygen in the arterial blood, hypoxia is defined as 
an undersupply of the body tissues with oxygen. Besides PaO2, the oxygen supply of body tissues 
depends on the cardiovascular system providing a certain level of tissue perfusion, which is frequently 
impaired in severe sepsis and septic shock. Hypoxia cannot be measured directly in the clinical routine, 
but since cells produce lactate when exposed to hypoxic conditions, the serum level of lactate is often 
used as a surrogate parameter for hypoxia. 
We formed two groups, separated by the population median of maximum Baseline serum lactate level, 
which was 2,75 mmol/l. When investigated for Day 0 cytokine release, there showed to be significant 
differences in most of the test panels stimulated with PWM or LPS, with a corresponding correlation as in 
our analysis of hypoxemia: the group of patients supposedly suffering from hypoxia (represented by a high 
serum lactate level) showed an impaired release of cytokines. Figure 10 shows the plots for TNF-α 
release in the PWM-stimulated assay and IL-1β release in the LPS-stimulated assay, respectively. 
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3.3.2.6. Demographic, biometric and epidemiologic aspects 
For further analysis of the patient collective regarding preexisting characteristics not directly linked to 
disease severity, we investigated correlations between cytokine release data and age, BMI, sex, infectious 
focus localization and pathogen type (gram-positive bacterial, gram-negative bacterial, viral). Concerning 
age and BMI, a few slightly significant differences between groups could be detected, none of which 
showed a consistent pattern (data not shown). None of the latter three analyses revealed a single 
divergence significant on the 0,05 significance level (data not shown). 
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3.3.3. Receiver operating characteristics 
Up to this point it could be determined that firstly - in comparison to healthy individuals - our patient 
collective was in a state characterized by cellular immune suppression. Secondly, we could point out that 
the degree of immune dysfunction correlated with inflammatory parameters, established objective markers 
of disease severity as well as conditions exerting immunodepressive effects. Our third step was to 
investigate whether our method had a predictive value regarding defined clinically highly relevant 
endpoints. 
3.3.3.1. Mortality 
With seven patients who could not entirely be followed up and 14 deaths among the patients who were 
followed up for the whole period of 90 days, overall mortality was 20 %. By employing Receiver operating 
characteristic (ROC) curves, the release of IFN-γ after stimulation with PWM allowed a statistically 
significant prediction of overall death risk, with lower IFN-γ release indicating higher mortality (Area under 
the receiver operating characteristic curve (AUC) = 0,72, p = 0,01; data not shown). The other read-outs, 
particularly our reference read-outs PWM - TNF-α and LPS - IL-1β, did not show any significant values in 
the ROC-analysis regarding mortality (Table 9, Figure 11). 
Compared to this, the disease severity classification systems SAPS II and APACHE II also did not reveal 
statistically significant predictability of mortality. Altogether characterized by p-values > 0,05, AUCs were 
0,61 for SAPS II Baseline and 0,64 for APACHE II Baseline (Table 9, Figure 11). 
When incorporating all of the parameters (PWM – TNF-α, LPS – IL-1β, serum IL-6, APACHE II, SAPS II) 
by mathematically combining them in a single ROC curve, however, a result scarcely significant on the 
0,05 significance level results. 
Table 9. Performance of different markers in ROC-analysis regarding 90-day mortality
 
Marker N AUC (95 % CI) p Cut off Sensitivity Specificity 
PWM - TNF-α 75 0,59 (0,44 – 0,75) > 0,05 < 29,4 pg/ml 79 % 44 % 
LPS - IL-1β 56 0,62 (0,43 – 0,81) > 0,05 < 40,5 pg/ml 67 % 64 % 
SAPS II 73 0,61 (0,42 – 0,79) > 0,05 > 82 36 % 90 % 
APACHE II 73 0,64 (0,49 – 0,79) > 0,05 > 25,5 86 % 44 % 
Serum IL-6 61 0,67 (0,51 – 0,84) > 0,05 > 1195 pg/ml 77 % 56 % 
PWM - TNF-α + APACHE 
II + serum IL-6 
61 0,63 (0,47 – 0,78) > 0,05 Fictious value 92 % 42 % 
All of the above combined 47 0,72 (0,54 – 0,89) < 0,05 Fictious value 75 % 60 % 
ROC: Receiver operating characteristic, AUC: Area under the receiver operating characteristic curve, CI: Confidence interval. 
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3.3.3.2. Initiation of renal replacement therapy 
Because of the rather small number of cases and the relatively low overall death rate of 20 %, we 
postulated another more frequent endpoint would partly compensate our lack of power and enable us to 
prove statistical significance. Acute renal failure (ARF) is a common complication of severe sepsis and 
septic shock and represents not only an indicator of disease severity, but also an independent risk factor 
for letality, occurring as often as 41 % in severe sepsis and septic shock in a 2007 prevalence study 
carried out in German ICUs [47]. According to German 2010 sepsis guidelines, indication for renal 
replacement therapy (RRT) in severe sepsis and septic shock has to be determined individually, but 
should be considered early, since diuretic agents don’t improve outcome. In addition, indication for RRT in 
severe sepsis and septic shock should be restricted to renal failure [13], which makes the initiation of RRT 
a good marker for severe, RRT-dependent ARF. In our patient collective, 35 % of patients received RRT 
during their stay on ICU (Table 7). 
For ROC-analyses regarding the endpoint “initiation of RRT during stay on ICU”, cytokine assay read-outs 
PWM - TNF-α and LPS - IL-1β, serum IL-6 level as well as disease severity classification systems SAPS II 
and APACHE II showed similar, very good results, characterized by high statistical significance (Figure 12, 
Table 10). A calculatory combination of serum IL-6 level with the cytokine read-out and disease severity 
classification system characterized by the best performance (namely PWM – TNF- α and APACHE II) 
further improved the test’s performance (AUC = 0,89). When combining all of the markers (PWM – TNF-α, 
LPS – IL-1β, serum IL-6, APACHE II, SAPS II) gathered at the very beginning of the disease, the resulting 
ROC-curve reaches an AUC of 0,93 with a p < 0,0001 and a sensitivity of 88% / specificity of 91% in 
identifying those patients who are most likely to require RRT during their disease process (Table 10, 
Figure 12). 
Table 10. Performance of different markers in ROC-analysis regarding initiation of RRT
a 
Marker N AUC (95 % CI) p Cut off Sensitivity Specificity 
PWM - TNF-α 75 0,77 (0,65 – 0,88) < 0,001 < 21,9 pg/ml 81 % 67 % 
LPS - IL-1β 56 0,75 (0,61 – 0,89) < 0,01 < 67,0 pg/ml 88 % 55 % 
SAPS II 74 0,82 (0,72 – 0,93) < 0,001 > 67,5 85 % 71 % 
APACHE II 74 0,83 (0,74 – 0,93) < 0,001 > 27,5 92 % 58 % 
Serum IL-6 62 0,72 (0,58 – 0,85) < 0,01 > 961 pg/ml 77 % 55 % 
PWM - TNF-α + 
APACHE II + serum IL-6 
62 0,89 (0,80 – 0,97) < 0,0001 
Fictious 
value 
82 % 88 % 
All of the above 
combined 
48 0,93 (0,85 – 1,00) < 0,0001 
Fictious 
value 
88 % 91 % 
a during ICU stay; ROC: Receiver operating characteristic, RRT: Renal replacement therapy, AUC: Area under the 
receiver operating characteristic curve, CI: Confidence interval. 
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4. Discussion 
4.1. Evaluation of the essential findings 
4.1.1. Patients versus control group 
In 2011, Tamayo et al. [48] could show - in a patient collective very much resembling that of our study - 
that in septic shock patients plasma levels of both pro- and anti-inflammatory cytokines such as IL-6, IL-8, 
IFN-γ, granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-10 were significantly increased 
shortly after the onset of septic shock as compared to healthy controls. However, the differences in 
functional immune performance as assessed by a cytokine release assay in a critically ill patient collective 
suffering from severe sepsis or septic shock in comparison to a healthy control group revealed a severe, 
general cellular immune dysfunction in the patient collective. This condition was represented by - for the 
most part - highly significant suppression of supernatant cytokine concentrations in all of the stimulated 
assays except for few cytokine read-outs. In conclusion, most of the patients were already in an 
immunosuppressive state at the time of study enrolment, namely within 24 hours after the onset of severe 
sepsis or septic shock.  
In SIRS, one would expect overwhelming inflammation and thus massive cytokine release exceeding the 
reference range defined by the healthy control group. Such a condition, however, was only present in very 
few patients who must be regarded as outliers considering the rest of the population. Consistent with 
Tamayo et al. [48], however, our patient collective simultaneously presented a severe rise in serum levels 
of  infection parameters determined in clinical intensive care routine like CRP or IL-6. The latter is a 
cytokine predominantly exerting pro-inflammatory effects, such as mediating T-cell activation and an 
acute-phase response (and thus inducing, among others, CRP) [37]. Median Baseline IL-6 was 1248 
pg/ml (Table 8), constituting a rise of more than 200-fold above the reference range, and none of our 
study patients had an IL-6 level within the reference range of < 5,9 pg/ml. Since IL-6 has a short plasma 
half-life, with statements in the literature ranging from minutes to hours [44, 49], it can be assumed that 
there was an ongoing cytokine production in vivo at the time of blood sample obtainment.  
At first appearance paradoxically, however, the same individuals’ in vitro whole blood cytokine response to 
strong immunologic stimulants was suppressed to a very low level as compared to healthy controls. 
Compared to the strong suppression of functional in vitro immune responses, the highly elevated plasma 
IL-6 levels can to some extent be explained by the fact that IL-6 is not only produced by immune cells, but 
also by endothelial cells, fibroblasts and keratinocytes. Therefore, in the case of such critical infectious 
conditions, IL-6 serves rather as a marker for tissue injury than as a specific marker for activation of the 
immune system [50]. Since, on the other hand, CRP is directly induced by IL-6 via the acute-phase 
response [51], its raised levels can also be explained by the finding above.  
As a conclusion, the tremendously elevated levels of the so-called “inflammatory markers” in conjunction 
with the simultaneous marked cellular immune dysfunction can be characterized as an ambivalent 
situation. On the one hand, the whole body seems to be immunologically “on fire”, with pro-inflammatory 
processes taking place, exponentiating themselves and thus resulting in tissue injury, organ failure and, as 
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a result, even more inflammation. The initial effect intentioned is not accomplished, however, since as 
negative feedback, anti-inflammatory processes are simultaneously initiated and upregulated, which result 
in severe leukocyte dysfunction. Consistently with this, recent studies tend to defeat the view of SIRS and 
CARS as two separate processes taking place one after another, as it was still postulated about ten years 
ago [52]. It is now believed that pro- and anti-inflammation are two concurrently developing processes 
emerging early in the pathophysiologic process [23, 48, 53], which are most commonly referred to as 
mixed antagonist response syndrome (MARS). 
In detailed consideration of the assays and cytokines affected, our data suggest that the innate immune 
response (e.g. as represented by the LPS assay) seems less compromised than the specific immunity. 
The occurrence of marked lymphocyte apoptosis in sepsis, whose quantity is determined by disease 
severity [54, 55], might serve as an explanation. Consistent with this, typical changes in the differential 
blood count develop, resulting in relative granulocytosis and lymphopenia (median lymphocytes: 6,5 % in 
our patient population; reference range: 25 % - 40 %; see Table 8). Secondly, increased numbers of 
regulatory T cells (Tregs) in sepsis are to some extent responsible for decreased T cell function and 
proliferation [17]. Following an enhanced ingestion of apoptotic lymphocytes by macrophages, their 
phenotype changes to anti-inflammation, with an increase in production of IL-10 and transforming growth 
factor β (TGF-β) as opposed to a decrease in release of pro-inflammatory mediators like TNF-α or IL-1β 
[56]. Both IL-10 and TGF-β affect T cells as well as macrophages in an inhibitory way [37]. Furthermore, 
the complex interlinkages between the innate and acquired parts of the immune system contribute to each 
other’s dysfunction via a lack of stimulation. Since, for example, the powerful macrophage activator IFN-γ 
is primarily produced by T cells, T cell apoptosis or dysfunction will secondarily result in macrophage 
dysfunction [57]. As a conclusion, initial lymphocyte apoptosis occurring early in sepsis results in the 
initiation of anti-inflammatory processes and discontinuation of immunostimulating processes, and thus 
secondarily also inhibits the innate immune system. 
An emphasis on anti-inflammatory processes can be reconstructed in our data using IL-10 release values.  
In the patient population, IL-10 secretion was less impaired than the release of pro-inflammatory cytokines 
(Figure 3). It is notable, however, that in all of our assays, the IL-10 release in severe sepsis or septic 
shock was either similar or even slightly compromised compared to the control group. An IL-10 secretion 
significantly exceeding the control group could not be demonstrated in any of our cytokine release assays. 
Still, as a result from massive impairment of pro-inflammation opposed to mild impairment of anti-
inflammation, the state of equilibrium shifts to anti-inflammation, which might be contributing to the state of 
immunosuppression in sepsis. 
For the Bacteria and Fungi assays, the high variability between patients regarding their whole blood 
response could be attributed to differences in prior antigen exposure, since the intensity of antigen 
exposure determines the quality and quantity of a subsequent immune response to the same antigens. A 
similar variability - although not quite as highly developed - is also present in the assays using unspecific 
stimulants, which do not depend on prior antigen exposure (Figure 2, Figure 3). Other studies have 
confirmed the presence of a high interindividual variability in cytokine release from whole blood [58]. 
However, each person seems to have a defined individual whole blood response, which is - within rather 
narrow limits - constant over the course of several weeks. It is postulated that the individual patient’s HLA-
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DR genotype, which is known to correlate with cytokine release, might play an important role [58]. This 
finding limits the interindividual comparability of whole blood response, imposes caution in interpreting the 
data and in fact complicates proving significant differences between independent samples. Instead, it 
suggests the monitoring of whole blood release kinetics for paired groups as a promising concept for 
further studies. 
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4.1.2. Subcohort-analyses 
As pointed out in 3.2.2, in assays addressing solely acquired immune pathways, no further sub-cohort 
analysis was possible due to a general suppression below the lower detection limit in the majority of 
cytokines and for most stimulation assays. Discrimination was possible, though, only in assays using 
strong polyclonal stimulants, such as LPS and PWM. In order to maintain comparability between single 
analyses - and to restrict the extent of this work to a usual dimension - we mostly limited the shown data in 
this field to two key cytokine read-outs, IL-1β and TNF-α, as measured from the assays stimulated with 
the substances named above – LPS and PWM. Both cytokines, IL-1β as well as TNF-α, are predominantly 
released by macrophages and mediate pro-inflammatory effects such as inducing fever, stimulating nitric 
oxide and prostaglandin synthesis and activating other immune cells. Furthermore, both cytokines induce 
each other’s and IL-6 synthesis and potentiate each other’s actions. They have very similar effects and 
are responsible for many of the constitutional responses to acute inflammation in innate immunity [15].  
 
4.1.2.1. Inflammatory markers 
Patients with moderate leukocytosis showed the best whole blood immune response, whereas both 
leukopenia as well as severe leukocytosis were associated with increased immune dysfunction (Figure 4). 
One possible explanation for this is the consideration of WBC as a marker of disease severity. Patients at 
both extreme ends of the spectrum - in leukopenia as well as severe leukocytosis - presumably are 
affected more seriously than patients with normal WBC or a moderate degree of leukocytosis, which 
serves as a physiologic reaction to an infection. Our data suggest that those patients with a higher disease 
severity show the worst whole blood immune response, which is consistent with our other findings. 
Another approach might be the duration of the infection, which was shown to be of high interest for the 
prediction of disease progression in a microsimulation model [59]. Owing to our study design, there is 
considerable difficulty in interpreting the time axis regarding the onset of (non-severe) sepsis, bacteremia 
or infection. None of the onsets of either of these conditions was documented in our study protocol, nor is 
in general easy to determine in clinical routine. The only condition documented was the fulfillment of 
severe sepsis or septic shock definition criteria, within 24 hours after which study enrolment was 
conducted. In the literature, there is relatively little information about the exact kinetics of septic conditions 
and inflammatory response, but murine sepsis models based on cecal ligation and puncture (CLP) 
showed that the systemic inflammatory response represented by elevated levels of pro-inflammatory 
cytokines in the blood plasma began to emerge within 2 – 8 hours after the insult, depending on the 
individual cytokine [60]. Anti-inflammatory processes are assumed to begin within the first 24 hours in 
human sepsis [61]. A possible hypothesis would be that those patients presenting a moderate rise in 
infection parameters and a better whole blood response were still in an earlier state shortly after onset of 
the infection, in which anti-inflammation and corresponding immune suppression was not as bold as in 
those patients in more progressed states. 
As already pointed out (in 4.1.1), the ambivalent behavior of IL-6 serum levels and corresponding whole 
blood response as demonstrated in Figures 5 and 6 can be attributed to the finding that in progressed 
phases of infectious conditions, the main incentive for the resulting “cytokine storm” is not a physiologic 
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reaction to pathogens but the massive liberation of so-called damage-associated molecular patterns 
(DAMPs). These are released following cellular injury, mainly from the human mitochondria, and have a 
high genetic and thus structural resemblance to the bacterial surface. The latter acts in a very similar way 
and constitutes the physiological activator of the immune response; it goes by the name pathogen-
associated molecular pattern (PAMP) [62-64].  
In summary, it can be stated that the degree of tissue injury and thus the disease severity, represented, 
among others, by a marked rise in inflammatory markers such as CRP and IL-6, is negatively correlated 
with the whole blood response to immunologic stimulants. This results in a heightened susceptibility to 
secondary infection and thus late-phase mortality. 
 
 
4.1.2.2. Disease severity classification systems 
Consistent with the findings named above, patients in higher disease severity - as quantified by the 
common disease severity classification systems SAPS II and APACHE II – were shown to have a 
significantly impaired whole blood response as compared to patients with less marked disease severity 
(Figure 7). This finding applied to the PWM - TNF-α assay as well as for the bacterial antigen mixture - 
TNF-α assay, which was included in Figure 7 for this reason. The LPS - IL-1β assay showed an 
analogous trend, but did not reach statistical significance (data not shown).  
Both of the applied scores are constructed in such a way that they mainly incorporate physiologic 
parameters which are typically deranged in case of organ failure and tissue injury – such as serum 
electrolytes and neurologic, hemodynamic, respiratory, renal and hepatic organ failure parameters [40, 
41]. As a conclusion, the results included in this section are equivalent to the aforementioned 
consideration of inflammatory parameters, using another method of quantifying the abstract term “disease 
severity”. 
 
 
4.1.2.3. Hydrocortisone administration 
Figure 8 reveals the highly significant suppression of pro-inflammatory cytokine release in the group of 
patients receiving relevant doses of hydrocortisone. Considering the indications as well as the effects of 
hydrocortisone, an ambivalent situation emerges.  
First of all, the pharmacologic effects exerted by hydrocortisone must be taken into account. 
Hydrocortisone has immunosuppressive effects mediated in a number of different ways, and thus causes 
considerable impairment in whole blood response. Since it’s pharmacokinetic elimination is dependent on 
renal and hepatic function [65], it can be assumed that there is pharmacologic activity for the whole in vitro 
incubation period of 48 hours. 
But one must also take into account that according to guidelines, the application of hydrocortisone should 
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be restricted to patients in refractory septic shock, in which hemodynamic stability cannot be restored by 
both adequate fluid resuscitation and usage of vasopressors [11, 13]. Within our patient collective, this 
condition affects those patients in the most progressed phase of septic shock and defines a high severity 
of disease. Accordingly, the group of patients receiving > 50 mg of hydrocortisone showed to have 
considerably higher SAPS II and APACHE II scores than the group of patients who did not receive 
relevant doses of hydrocortisone. In part, the differences between the two groups could thus be caused by 
patient selection in accordance with the indication for hydrocortisone therapy in septic shock. 
 
 
4.1.2.4. Hypoxemia and hypoxia 
As demonstrated in Figure 9, hypoxemia significantly suppressed the immune response in our study 
population. The same goes for elevated levels of serum lactate as a surrogate parameter for hypoxia, 
accordingly. Choukèr et al. could show that there is a hypoxia-induced anti-inflammatory mechanism 
mediated by the A2 adenosine receptor (A2AR), which results in a reduction of lung tissue damage in 
patients with acute respiratory distress syndrome (ARDS) as well as the systemic effect of reducing 
inflammatory liver injury in A2AR-competent mice [45, 46]. These anti-inflammatory effects are 
accomplished by different mechanisms including the inhibition of oxidative burst, a reduction in platelet 
activation and thus in microvascular occlusion, a reduced release of pro-inflammatory cytokines such as 
TNF-α or IFN-γ opposed to an increased release of anti-inflammatory cytokines such as IL-10 or IL-4 and 
thus a shift of the lymphocyte TH1/TH2-equilibrium towards  the TH2-pathway [66, 67]. Adequate 
oxygenation thus seems like an important component of a profound sepsis therapy. 
Caution is imposed, however, regarding the causality of effects. Especially considering the serum lactate 
level, not only respiratory insufficiency can be made accountable for its rise. Circulatory failure resulting in 
tissue hypoperfusion as well as tissue damage also result in increased lactate levels, two conditions which 
typically characterize progressed septic conditions independently from the respiratory situation. 
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4.1.3. Receiver operating characteristics 
Our reference cytokine read-outs PWM – TNF-α and LPS – IL-1β provided results comparable to 
multifactorial disease severity classification systems and an established inflammatory marker determined 
in blood serum (IL-6) in predicting different outcome measures (as shown in Tables 9 - 10 and Figures 11 
- 12). 
In the case of 90-day mortality, however, no isolated marker was capable of providing statistically 
significant results. This is most likely due to our small sample size combined with the fact that our patient 
population presented a low overall mortality of 20%, one third of which represented late phase mortality 
characterized by death causes associated with complications in the disease process and in some cases 
even comorbidities with no or little connection to sepsis. Still, the mathematical combination of all markers 
used provided a statistically significant result allowing a prognosis for the chances of death at the very 
beginning of the disease. 
These results could be considerably improved when looking at the presence of marked acute renal failure 
in the course of the disease, represented by the initiation of renal replacement therapy. This is a common 
complication of severe septic conditions and thus more closely associated with the severity of disease 
progress than overall mortality, which tends to be confounded by various independent variables. In 
consideration of the endpoint “initiation of renal replacement therapy in the disease progress”, all of the 
parameters showed a good predictive value with high statistical significance. These solitary results could 
yet be outperformed by a calculatory combination of different markers, resulting in p-values < 0,0001 and 
an area under the receiver operating characteristic curve of up to 0,93.  
These findings suggest that the whole blood response to strong immunologic stimuli might be a powerful 
supplement to established markers and scoring systems in sepsis. The combination of parameters 
showed to have eminent prognostic value in our study population. Solitary parameters, even though 
characterized by a strong positive correlation among one another, seem to complement each other. In 
clinical routine, this could be used to identify patients at high risk for an especially severe clinical course 
and to adjust different treatment strategies early, as specified in the following section. 
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4.2. Conclusions for diagnostics and therapy in sepsis 
Besides the standard therapy for sepsis - including early anti-infective therapy, focus control and 
adjunctive therapies aiming at stabilizing the patient’s vital functions - a variety of different therapeutic 
approaches targeting the immune response have been tested. The focus of these interventions originally 
lay on counteracting the hyperinflammatory cytokine storm by immunomodulation in a negative way, i.e. 
by administering antibodies directed against TNF-α or other pro-inflammatory cytokines [68], absorption of 
cytokines from the blood plasma [69] or hydrocortisone administration in high as well as in low doses [17]. 
Up to the present day, none of these attempts showed to be promisingly successful regarding mortality in 
controlled clinical trials. With the focus of clinical research concentrating on the immunosuppressive state 
characterizing the course of sepsis, recent trials included the contrary approach of immunostimulation, 
using for example granulocyte-macrophage colony-stimulating factor (GM-CSF) or IFN-γ in patients with 
verified immune dysfunction [70-72]. Despite being a concept with first promising results, dating as far 
back as to the year 1997 [71], conclusive results supporting this approach are still pending to the present 
day due to a lack of sufficiently powered controlled clinical trials. 
 
 
4.2.1. Hygiene and reverse isolation 
Our data suggest that from the first moments after onset of septic shock, immune competence is severely 
limited. The degree of this immunologic dysfunction positively correlates with disease severity, levels of 
inflammatory parameters, presence of hypoxemia and administration of hydrocortisone. Thanks to modern 
intensive care medicine, most patients treated in an ICU nowadays survive the first phase of septic shock 
characterized by hypotension and sequential organ failure due to supportive measures compensating 
circulatory and organ failure. A notable number of deaths, however, occur in later phases of the disease 
course and can be attributed to the sequelae of immunosuppression [57]. It could be demonstrated that 
patients suffering from critical illness and associated immune suppression are target to secondary 
infections not only by virulent organisms like Clostridium difficile or Staphylococcus aureus but also by 
opportunistic pathogens like Stenotrophomonas maltophila, Acinetobacter calcoaceticusbaumannii and 
Candida albicans as well as reactivation of cytomegalovirus (CMV) and herpes simplex virus (HSV) [57, 
73-75]. 
An expansion of antiinfective treatment does not seem appropriate when facing this issue. As soon as one 
organism is defeated by antibiotics, antimycotics or virostatic agents, another one which is not affected by 
the drugs applied will lead to a superinfection [57], which is especially favored by the fact that those 
pathogens tend to be multidrug-resistant [75]. In order to minimize the hazard of acquiring an opportunistic 
infection, first of all more basic methods seem promising. Patients for sure do benefit from strict 
compliance to hygienic regulations. More efforts should be taken to create a better awareness for this 
issue in the field of medical staff, especially in ICUs. Moreover, in the patients most at risk for secondary 
infection, temporary reverse isolation - as is typically employed in other patient collectives in 
immunosuppression - might have beneficial effects, though a recent review was able to show that the 
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incidence of errors in drug administration, a delay in examinations such as CT-scans, noncompliance and 
adverse events was increased in patients under isolation [76].  
 
 
4.2.2. Restriction of hydrocortisone administration 
Secondly, the indication for applying hydrocortisone in sepsis should be strictly questioned, since it can be 
considered capable of further weakening the immune response. Both high-dose as well as low-dose 
administration of corticosteroids were performed in previous times, none of which showed conclusive 
improvement in survival [77, 78]. There exists some evidence, however, that an earlier reversal of shock 
may be accomplished by corticosteroid application [78-80]. A 2008 randomized controlled trial showed 
that neither a survival benefit nor an increase in the rate of shock reversal could be accomplished by 
administration of hydrocortisone in septic shock. It could yet be demonstrated that in those patients 
experiencing shock reversal, shock reversed earlier under treatment with hydrocortisone, entailing higher 
rates of secondary infections including a recurrence of septic shock, however [80]. 
Hence, in the latest guidelines, only minor recommendation exists for corticosteroid administration, which 
is restricted to cases of refractory septic shock which do not respond adequately to fluid resuscitation and 
vasopressor therapy [11, 13]. In summary it can be said, therefore, that if possible, the use of 
corticosteroids in sepsis should be re-visited on its benefits and risks to potentially prevent possible 
detrimental effects to the immune system. 
 
 
4.2.3. Immune function monitoring and modulation 
Another approach strongly suggested by our study data, which is being increasingly discussed lately, 
implies actually reactivating the depressed immune system, guided on the basis of patients’ actual 
immune status. Previous approaches to immune monitoring in sepsis implied the measurement of HLA-
DR expression on monocytes and, similar to the method applied in our study, of in vitro TNF-α release in 
whole blood following stimulation with LPS. In patient collectives initially being in an immunosuppressed 
state as measured by the criteria named above, the application of GM-CSF or IFN-γ, respectively, was 
able to restore monocytic HLA-DR expression as well as the in vitro whole blood response besides 
showing clinical benefits as far as can be assessed from the published data [71, 72]. These early studies 
were neither randomized trials nor sufficiently powered to demonstrate survival benefits, though. In a 
meta-analysis from 2011, no significant effect from the administration of granulocyte colony stimulating 
factor (G-CSF) or GM-CSF on 28-day mortality could be shown. In the therapy groups, however, a 
significant increase in the rate of reversal from infection could be demonstrated [81]. However, a critical 
review addressing the meta-analysis mentioned above faults methodical deficiencies and calls for 
subsequent sufficiently powered randomized controlled trials to prove a mortality reduction [82]. The latest 
review on the topic, published in 12/2015, came to the conclusion that in the absence of deleterious side 
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effects by GM-CSF administration in sepsis patients, multiple clinical benefits such as more rapid recovery 
from infection, a decrease in length of hospital stay and in requirement of mechanical ventilation could be 
shown [83]. A conclusive prove of mortality reduction could not be delivered up to the present day, 
however, which might be attributed to inconsistencies in patient screening for signs of immune 
suppression, missing differentiation of patient populations and the absence of long-term follow-up [83]. 
Nevertheless, immune stimulatory therapies in sepsis are a promising new concept and seem eligible to 
become the next milestone in sepsis therapy advancements.  
Another implication from our study data is the implementation of new risk stratification systems utilizing 
cytokine release data in order to assess prognosis regarding the disease progress. As we could show in 
the ROC-section, whole blood response data were equivalent in performance to established sepsis 
markers and disease severity classification systems and their addition eminently improved performance of 
ROC analyses. 
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4.3.  Limitations and considerations 
4.3.1. No adjustment for confounding variables 
First of all it is notable that we did not adjust for confounding variables. Having a closer look at the results 
section for inter-patient correlations (3.2.2), it is apparent that most of the parameters examined show a 
correlation with disease severity, which could be regarded as a confounding variable in this context. More 
severely affected individuals tend to show more distinct alterations when it comes to inflammatory 
parameters, are more likely to fulfill the criteria for an indication for hydrocortisone, tend to be more 
impaired in regard to respiration and gas exchange with consecutive hypoxemia and hypoxia and 
obviously show higher scores in the disease severity classification systems applied. In conclusion, it is not 
legitimate to attribute between-group differences in immune response solely to the one parameter 
investigated in the individual case, and such comparisons have to be treated with caution. 
 
4.3.2. Cytokine values partly below the lower detection limit 
Secondly, as mentioned in the methods section, in some assays most of the cytokine release values in the 
patient population showed values out of range below, i.e. below the lower detection limit. In order not to 
eliminate most of the values for the concerned assays, we used the lower detection limit in place of 
individual values, which were not providable with the laboratory methods applied. This missing 
differentiation in the low value range, affecting a substantial portion of the values incorporated in our 
calculations, to some extent limits the statistical power as well as the validity and interpretation of the data 
in this very low range. 
 
4.3.3. Missing information about the time of infection onset 
Owing to our study design, the only specific moment in time documented was the onset of severe sepsis 
or septic shock, marked by beginning organ failure or hypotension, 24 hours after which study enrolment 
had to be conducted. The period of time in which infection was already present before fulfilling the severe 
sepsis/septic shock criteria, however, cannot be reconstructed from our data. This limits comparability 
between single patients and especially statements concerning the time scale of immunologic processes in 
sepsis.  
 
4.3.4  Consideration of the new Sepsis-3 definitions 
With the SISPCT trial being conducted before publication of the Sepsis-3 definitions [4, 25], the inclusion 
criteria and thus data analysis naturally were based on the former ACCP/SCCM definitions [2] valid at that 
time. We thus did not considerate Sepsis-3 definitions in the course of this work. It is to say, however, that 
our findings on the behavior of immune function in sepsis and the importance of end organ failure for the 
progression of sepsis are supported by the statements of the Sepsis-3 publication [4]. 
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5. Summary 
Despite great efforts on research on sepsis, it is still among the leading causes of death [1] and 
constitutes the leading cause of morbidity and mortality of patients dependent on intensive care treatment 
[84]. Most deaths due to sepsis occur in later phases, days after the onset of the disease [85], and seem 
to be attributable to sepsis-induced alterations of the immune response [84, 86]. In order to closer 
investigate the alterations affecting the immune system in severe septic conditions, we prospectively 
enrolled 76 patients with severe sepsis or septic shock, respectively, and eleven healthy individuals as a 
control group. For the purpose of monitoring their cellular leukocyte responsiveness, whole blood 
withdrawn shortly after the onset of severe sepsis or septic shock, respectively, was incubated for 48 
hours without stimulation or stimulated with different agents addressing the innate or acquired parts of the 
immune system. Subsequently, supernatant cytokine concentrations were measured. Results were 
correlated with clinical data.  
As opposed to the control group, the patient population presented marked immune dysfunction with an 
emphasis on the acquired immune system. In contrast, anti-inflammatory markers were relatively 
upregulated. Within the patient population, those with higher inflammatory markers, higher disease 
severity scores, exposure to hypoxemia/hypoxia and hydrocortisone administration showed a more 
pronounced decrease in immune function. Whole blood response data showed similar performance to 
established markers and classification systems in predicting those patients with fatal outcome and those in 
future need of renal replacement therapy due to acute renal failure. The different markers seem to 
complement each other and in combination provided a superior performance. 
The view of systemic inflammation and anti-inflammation as two separate processes developing 
subsequently has to be reconsidered in favor of being two concurrently developing processes emerging 
early within the disease progress. Further advances in sepsis therapy with focus on immune status are 
needed to improve outcome. Those should incorporate adequate oxygenation, hygienic measures and 
consideration of reverse isolation, strict indication for corticosteroids and especially immunomodulatory 
therapies restoring immune function. 
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6. Zusammenfassung in deutscher Sprache 
Trotz großer Forschungsaufwendungen rangieren septische Erkrankungen nach wie vor weit oben in den 
Todesursachenstatistiken [1] und stellen die häufigste Ursache für Morbidität und Mortalität für auf 
Intensivstationen behandelte Patienten dar [84]. Die meisten Sepsis-bedingten Todesfälle sind in der 
Spätphase, Tage nach dem Ausbruch der Erkrankung, zu verzeichnen [85], und scheinen in 
Zusammenhang mit durch die Erkrankung bedingten Veränderungen der Immunantwort zu stehen [84, 
86]. Um diese im Rahmen schwerer septischer Erkrankungen auftretenden Veränderungen näher zu 
untersuchen wurden prospektiv 76 Patienten mit schwerer Sepsis bzw. septischem Schock und elf 
gesunde Kontrollen rekrutiert. Zum Zweck der Untersuchung ihrer zellulären Immunität wurde kurz nach 
Einsetzen der schweren Sepsis bzw. des septischen Schocks Vollblut gewonnen und für 48 Stunden nativ 
oder nach Versetzen mit verschiedenen Stimulanzien der angeborenen sowie der erworbenen Immunität 
inkubiert. Anschließend wurden die Zytokinkonzentrationen im Überstand gemessen und die Ergebnisse 
mit klinischen Patientendaten in Beziehung gesetzt. 
Verglichen mit der Kontrollgruppe zeigte das Patientenkollektiv eine ausgeprägte Dysfunktion der 
Immunantwort mit Betonung des erworbenen Immunsystems. Gegensätzlich hierzu stellte sich eine 
relative Hochregulation anti-inflammatorischer Parameter dar. Innerhalb des Patientenkollektivs war eine 
ausgeprägtere Einschränkung der Immunantwort bei jenen Patienten nachweisbar, die höhere 
laborchemische Entzündungsparameter und eine höhere Krankheitsschwere aufwiesen sowie Hypoxämie 
bzw. Hypoxie ausgesetzt waren und therapeutisch Hydrokortison verabreicht bekamen. Die von uns 
erhobenen Daten zur zellulären Immunität zeigten sich in der Vorhersage letaler Verläufe sowie der 
Notwendigkeit von Nierenersatztherapie aufgrund akuten Nierenversagens im weiteren Krankheitsverlauf 
etablierten Scoring-Systemen zur Krankheitsschwereeinschätzung sowie etablierten Sepsis-Markern nicht 
unterlegen bzw. scheinen sich gegenseitig zu ergänzen. In Kombination zeigten die verschiedenen 
Marker ein jedem einzelnen Marker deutlich überlegenes Ergebnis. 
Die Betrachtung von Inflammation und Anti-Inflammation als zwei getrennte, nacheinander ablaufende 
Prozesse muss zugunsten eines Modells der Koexistenz zweier sich parallel bereits im frühen 
Krankheitsverlauf entwickelnder Prozesse überdacht werden. Weitere Fortschritte in der Therapie der 
Sepsis mit dem Hauptaugenmerk auf Immunprozessen sind notwendig, um die Prognose weiter zu 
verbessern. Diese sollten eine ausreichende Oxygenierung, die Optimierung der Krankenhaushygiene 
sowie die Erwägung von Umkehrisolationsmaßnahmen, eine strenge Indikationsstellung für 
Kortikosteroide und insbesondere immunomodulatorische Therapieansätze, die auf die Wiederherstellung 
der Immunkompetenz ausgerichtet sind, beinhalten. 
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7. List of abbreviations 
°C Degrees Celsius 
µg microgram 
µl microliter 
A2AR A2A adenosine receptor 
ACCP American College of Chest Physicians 
ALAT Alanine aminotransferase 
ANOVA Analysis of variance 
APACHE II Acute Physiology And Chronic Health 
Evaluation II 
ARDS Acute respiratory distress syndrome 
ARF Acute renal failure 
ASAT Aspartat aminotransferase 
AUC Area under the (receiver operating 
characteristic) curve 
Bacteria Bacterial antigen mixture 
BE Base excess 
BMI Body Mass Index 
bpm Beats per minute 
CARS Compensatory anti-inflammatory response 
syndrome 
CBA Cytometric bead array 
CD Cluster of Differentiation 
CD3/28 Human T-activator CD3/CD28 
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CI Confidence interval 
CLP Cecal ligation and puncture 
CMV Cytomegalovirus 
DAMP Damage-associated molecular pattern 
DNA Deoxyribonucleic acid 
DTH Delayed type hypersensitivity 
FiO2 Fraction of inspired oxygen 
Fungi Fungal antigen mixture 
GCS Glasgow Coma Scale/Score 
GM-CSF Granulocyte-macrophage colony-stimulating 
factor 
GOT Glutamic oxaloacetic transaminase 
GPT Glutamate-pyruvate transaminase 
HIV Human immunodeficiency virus 
HSV Herpes simplex virus 
HV Healthy volunteer 
ICU Intensive care unit 
IFN Interferon 
IL Interleukin 
IQR Interquartile range 
JAMA Journal of the American Medical Association 
kPa kilopascal 
LPS Lipopolysaccharide 
MAP Mean arterial (blood) pressure 
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MARS Mixed antagonist response syndrome 
MFI Mean fluorescence intensity 
ml millilitre 
ml/kg/h Millilitres per kilogram body weight per hour 
mm3 Cubic millimeters 
mmHg Millimeters of mercury 
mmol/l millimoles per liter 
MODS Multiple organ dysfunction syndrome 
n Number of cases 
NASA National Aeronautics and Space 
Administration 
paCO2 Arterial partial pressure of carbon dioxide 
PAMP Pathogen-associated molecular pattern 
PaO2 Arterial partial pressure of oxygen 
PCT Procalcitonin 
PMA Phorbol 12-myristate 13-acetate 
ROC Receiver Operator Characteristics 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute medium 
RRT Renal replacement therapy 
SAPS II Simplified Acute Physiology Score II 
SCCM Society of Critical Care Medicine 
SD Standard deviation 
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Sepsis-3 The third international consensus definitions 
for sepsis and septic shock 
SIRS Systemic inflammatory response syndrome 
SISPCT Placebo Controlled Trial of Sodium Selenite 
and Procalcitonin Guided Antimicrobial 
Therapy in Severe Sepsis 
SS Study patients suffering from severe sepsis or 
septic shock 
Th Helper T cell 
TLR Toll like receptor 
TNF Tumor necrosis factor 
Treg Regulatory T cell 
US, USA United States (of America) 
WBC White blood count 
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8. Register of figures 
Figure 1: Dependency of survival on the early initiation of antimicrobial therapy. From: Kumar et al., 2006 
[12] 
Figure 2: Patients versus control group in unstimulated assay and after stimulation with recall antigens 
and PWM 
Figure 3: Patients versus control group after stimulation with LPS, PMA and CD3/28 
Figure 4: Relationship between white blood count and IL-1β release after stimulation with LPS 
Figure 5: Relationship between serum IL-6 and IL-1β release after stimulation with LPS 
Figure 6: Relationship between serum IL-6 and TNF-α release in Basal and PWM assay 
Figure 7: Relationship between disease severity and TNF-α release in Bacteria and PWM assay 
Figure 8: Relationship between hydrocortisone administration and cytokine release 
Figure 9: Relationship between PaO2 and cytokine release 
Figure 10: Relationship between lactate level and whole blood response 
Figure 11: ROC curves for the endpoint 90-day mortality 
Figure 12: ROC curves for the endpoint “RRT during ICU stay” 
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9. Register of tables 
Table 1: Definition criteria for sepsis-associated conditions 
Table 2: SISPCT criteria for severe sepsis and septic shock 
Table 3: Demographic and biometric characteristics of patients versus control group 
Table 4: Sepsis and admission type characteristics 
Table 5: Microbiological and infection characteristics 
Table 6: Baseline medical status 
Table 7: Outcome characteristics 
Table 8: Baseline laboratory values 
Table 9: Performance of different markers in ROC-analysis regarding 90-day mortality 
Table 10: Performance of different markers in ROC-analysis regarding initiation of RRT 
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